3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Prostatic Neoplasms
5
Breast Neoplasms
5
Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
mCRPC
1
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hepatoblastoma
1
Hemangiosarcoma
1
Extensive Stage Lung Small Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
44
Carboplatin
35
Paclitaxel
27
Specimen Handling
18
Cyclophosphamide
16
Capecitabine
16
Magnetic Resonance Spectroscopy
14
sacituzumab govitecan
13
Gemcitabine
13
Taxes
12
Biopsy
12
130-nm albumin-bound paclitaxel
11
Albumin-Bound Paclitaxel
9
Doxorubicin
8
olaparib
7
Nivolumab
7
fludarabine
6
Cisplatin
6
eribulin
5
atezolizumab
5
Radiotherapy
5
Docetaxel
5
durvalumab
4
Fulvestrant
4
Epirubicin
4
Bevacizumab
4
veliparib
3
famitinib
3
abemaciclib
3
Vinorelbine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
talazoparib
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled